February 11, 2020 / 10:32 AM / 9 days ago

BRIEF-QuiapPEG Pharmaceuticals Holding Presents Positive Preclinical Results For QPG-1029

Feb 11 (Reuters) - QuiaPEG Pharmaceuticals Holding AB :

* PRESENTS POSITIVE PRECLINICAL RESULTS FOR QPG-1029

* THE RESULTS MEAN THAT QUIAPEG CONTINUES THE DEVELOPMENT PROGRAM FOR QPG-1029

* RESULTS FROM PRECLINICAL STUDY SHOW FOR THE FIRST TIME THAT QPG-1029 CAN BE ABSORBED IN BLOOD CIRCULATION AFTER INJECTION

* AFTER EVALUATION OF TREATMENT EFFECT IN PROOF-OF-CONCEPT STUDY CO IS TO CONDUCT PHARMACOKINETIC STUDIES WITH REPEATED DOSING, COMPLETE WITH TOXICOLOGY AND SAFETY STUDIES TO BE PERFORMED BEFORE CLINICAL PROGRAM WILL START

* RESULTS FROM PRECLINICAL STUDY SHOW THAT THE DRUG LIRAGLUTID IS RELEASED IN BLOOD PLASMA AFTER BOTH INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below